EVOLVEIMMUNE THERAPEUTICS
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.
EVOLVEIMMUNE THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2018-01-01
Address:
Westport, Connecticut, United States
Country:
United States
Website Url:
http://www.evolveimmune.com
Total Employee:
1+
Status:
Active
Contact:
+1 203 858 7389
Email Addresses:
[email protected]
Total Funding:
17.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Current Employees Featured
Founder
Investors List
Elm Street Ventures
Elm Street Ventures investment in Venture Round - EvolveImmune Therapeutics
Takeda Ventures
Takeda Ventures investment in Venture Round - EvolveImmune Therapeutics
Pfizer
Pfizer investment in Venture Round - EvolveImmune Therapeutics
Solasta Ventures
Solasta Ventures investment in Venture Round - EvolveImmune Therapeutics
Yonjin Venture
Yonjin Venture investment in Venture Round - EvolveImmune Therapeutics
Official Site Inspections
http://www.evolveimmune.com
- Host name: 183.206.174.34.bc.googleusercontent.com
- IP address: 34.174.206.183
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "EvolveImmune Therapeutics"
Leadership - EvolveImmune
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients.See details»
EvolveImmune Therapeutics - Crunchbase Company …
EvolveImmune Therapeutics develops an immunobiological platform that delivers both sustained immune activation and tumor cell targeting in a single agent.See details»
EvolveImmune Therapeutics - LinkedIn
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes …See details»
Our Pipeline - EvolveImmune
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients.See details»
EvolveImmune Therapeutics Provides Corporate and Program
Dec 13, 2023 EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer …See details»
EvolveImmune Therapeutics Provides Corporate and Program …
Dec 13, 2023 EvolveImmune intends to use the proceeds from this fundraising to support continued platform and pipeline development including the advancement of its lead multi …See details»
EvolveImmune Therapeutics Presents New Preclinical and …
Nov 11, 2024 EvolveImmune continues to progress its chemistry, manufacturing, and control (CMC) activities for EVOLVE104, with the goal of advancing the program into the clinic in …See details»
EvolveImmune Therapeutics Presents New Preclinical and
Nov 6, 2023 Contacts: EvolveImmune Therapeutics Stephen Bloch, M.D. Chief Executive Officer 860-856-7104 Vida Strategic Partners (on behalf of EvolveImmune Therapeutics) Tim Brons …See details»
Our Science - EvolveImmune
Through integrated T cell signaling, EvolveImmune’s first-in-category biologics directly target tumor cells and provide potent, tissue-localized immune amplification at the tumor site to …See details»
EvolveImmune Therapeutics Provides Corporate and Program …
Dec 13, 2023 EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer …See details»
EVOLVE-104 - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 Poster Presentations Spotlight Differentiated Therapeutic Profile and Precision Therapeutic Strategy for Lead Development Candidate EVOLVE104 as Program Advances …See details»
AbbVie and EvolveImmune Therapeutics Announce Collaboration …
Oct 31, 2024 EvolveImmune's proprietary EVOLVE platform is designed to deliver potent, selective and integrated T-cell co-stimulation to amplify and sustain the tumor killing capacity …See details»
AbbVie and EvolveImmune Therapeutics Announce Collaboration …
Oct 31, 2024 About EvolveImmune Therapeutics . EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics …See details»
EvolveImmune Therapeutics Presents Promising Preclinical Data …
Oct 24, 2022 EvolveImmune’s team showed that coordinated T cell receptor and CD2 engagement induced by the formation of an integrated synthetic immune synapse on human T …See details»
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 AbbVie has opened its bet on EvolveImmune’s ability to crack the puzzles with $65 million upfront. The deal features up to $1.4 billion in aggregate option fees and milestones, …See details»
EvolveImmune Therapeutics Enters into Strategic Research
Jun 14, 2023 EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer …See details»
EvolveImmune Therapeutics Enters into Strategic Research …
Jun 14, 2023 EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer …See details»
AbbVie and EvolveImmune Partner to Advance Next-Gen Cancer ...
Nov 20, 2024 AbbVie and EvolveImmune Therapeutics have entered a strategic collaboration to advance immuno-oncology therapies aimed at overcoming resistance to current cancer …See details»
News - EvolveImmune
Mar 23, 2023 At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients.See details»